Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.

Reuters NewMedia - November 28, 2005
Ben Hirschler, European Pharmaceuticals Correspondent

Europe's biggest drug maker and France's Institut Pasteur intend to make the vaccine by fusing genes from the human immunodeficiency virus (HIV) onto an existing vaccine for the childhood disease, the two organizations said on Monday.

GSK Biologicals -- Glaxo's vaccines unit -- will license the measles vaccine vector, or carrier, technology from Institut Pasteur, and researchers from both groups will jointly develop the new vaccine.

The project is the latest in a range of novel approaches to fighting HIV, which has killed more than 3.1 million people this year alone.

Scientists believe a vaccine is the best hope for ending the epidemic. However, the virus has proved a far more difficult for vaccine developers to outwit than anyone anticipated when the first case of HIV/AIDS was reported in 1981.

Glaxo believes adapting a measles shot is a promising approach, since the vaccine against this old disease is known to give very long-lasting immunity.

The hope is that using it as a carrier to deliver HIV proteins will produce a similarly potent and long-lasting vaccine to prevent AIDS.

The are no guarantees of success, however, and the project will take many years of research before scientists know whether they can manufacture a safe and effective therapy.

PUBLIC-PRIVATE PARTNERSHIP

The research will be carried out under a public-private collaboration, and the initial project is being supported by a grant of 5.5 million euros from the European Union.

Four research centers will be involved in France, Belgium and Britain, and the partners hope to start clinical studies in about three years.

Public-private partnerships are increasingly being used to tackle diseases, including malaria and tuberculosis, that occur primarily in poor countries where Western pharmaceutical companies stand little chance of making money.

In exchange for public sector support, companies agree to make any successful medicines available in developing countries at affordable prices.

Glaxo, like many of its rivals, is pursuing a number of different AIDS vaccine ideas.

Earlier this year it signed a collaboration with the International AIDS Vaccine Initiative to develop a vaccine using an adapted chimpanzee virus, known as an adenovirus, to carry HIV proteins into cells and trigger an immune response.

It also has a third in-house AIDS vaccine project, and experts believe any successful AIDS vaccine might have to combine a number of such different approaches.

Other companies are also stepping up work in the hunt for a vaccine, with Merck & Co. inc. arguably leading the field.

In September this year the U.S. company said it was doubling enrolment into a clinical trial of its leading AIDS vaccine candidate following encouraging initial results, though final results of the trial will not be available until at least 2008.

051128
RE051133

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .